News - Page 3

Cellares is partnering with Taiwanese biotech GenomeFrontier Therapeutics to evaluate the integrated contract developer and manufacturer’s cell shuttle platform for use in the production of virus-free CAR-T therapies.

GSK is consolidating two of its influenza vaccine manufacturing sites into one, leaving hundreds of jobs at risk.

As Samsung Biologics works to close a massive buyout to branch out into peptides, the Korean CDMO’s bread-and-butter contracting work continues to gin up big-ticket contracts from the drug industry.

Late August has been rough for IV solution makers as B. Braun added to its recall tally once more, building on Baxter’s three recalls of similar products in the same time frame.

Bristol Myers Squibb will spend $173 million to build a second radiopharmaceutical manufacturing facility in Indiana to couple with its current site in Indianapolis. The new plant will be in nearby Whitestown.

Artis BioSolutions opened the doors to a new manufacturing center located in Bilbao, Spain, that expands the CDMO’s production capabilities in next-generation genetic medicines.

After issuing a recall of thyroid tablets last week, Vitruvias Therapeutics of Alabama has closed up shop. Meanwhile, Baxter has initiated recalls of three products this week because of particulate matter.

Roche will invest $750 million to double the size of its Genentech unit’s manufacturing facility in Hillsboro, Oregon. The new outlay will support the construction of a fill-finish plant that will produce

The summer of the high-potency active pharmaceutical ingredient expansion continues, as yet another manufacturing specialist makes inroads to boost capacity for sensitive, in-demand drug ingredients.

After receiving a checkered regulatory scorecard in 2024, Aurobindo’s sterile injectables and oncology unit is back in the FDA’s crosshairs.